Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3524956,Elimination half-life,"Elimination half-life is approximately 7 hours in normal subjects and patients, but is prolonged in patients with renal insufficiency (creatinine clearance less than 60 ml/min).",Clinical pharmacokinetics of disopyramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524956/),h,7,5705,DB00280,Disopyramide
,6502472,binding,The binding of disopyramide varied between 60 and 92% in patients and between 81 and 88% in normal subjects at postequilibrium drug concentrations of 10(-7) M.,Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),%,60 and 92,13000,DB00280,Disopyramide
,6502472,binding,The binding of disopyramide varied between 60 and 92% in patients and between 81 and 88% in normal subjects at postequilibrium drug concentrations of 10(-7) M.,Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),%,81 and 88,13001,DB00280,Disopyramide
,6502472,association constant,"The association constant for the first binding site in serum from normal subjects and patients averaged 8.7 X 10(5) M-1 and 4.4 X 10(5) M-1, respectively (p less than 0.05).",Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),1/[M],8.7 X 10(5),13002,DB00280,Disopyramide
,6502472,association constant,"The association constant for the first binding site in serum from normal subjects and patients averaged 8.7 X 10(5) M-1 and 4.4 X 10(5) M-1, respectively (p less than 0.05).",Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),1/[M],4.4 X 10(5),13003,DB00280,Disopyramide
,6502472,unbound clearance,The unbound clearance of disopyramide averaged 277 ml/min and 209 ml/min in normal subjects and in patients (p less than 0.05).,Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),[ml] / [min],277,13004,DB00280,Disopyramide
,6502472,unbound clearance,The unbound clearance of disopyramide averaged 277 ml/min and 209 ml/min in normal subjects and in patients (p less than 0.05).,Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),[ml] / [min],209,13005,DB00280,Disopyramide
,6502472,elimination half-life of unbound concentrations,"The elimination half-life of unbound concentrations in normal subjects and in patients averaged 4.9 and 6.1 h, respectively (p less than 0.05).",Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),h,4.9,13006,DB00280,Disopyramide
,6502472,elimination half-life of unbound concentrations,"The elimination half-life of unbound concentrations in normal subjects and in patients averaged 4.9 and 6.1 h, respectively (p less than 0.05).",Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),h,6.1,13007,DB00280,Disopyramide
,6502472,bioavailability,"Although the bioavailability of disopyramide averaged 0.85 in both groups, it was more variable in patients owing to the variability in the fraction of the dose absorbed.",Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502472/),,0.85,13008,DB00280,Disopyramide
,921413,gastrointestinal absorption,The gastrointestinal absorption of [14C]-DPP was 86% as determined from the areas under the plasma total-14C concentration-time curves following 10 mg/kg oral or i.v. administration.,Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/921413/),%,86,18297,DB00280,Disopyramide
,1761078,clearance,There was enantioselective clearance of unbound disopyramide (0.39 l.h-1.kg-1 for R-disopyramide and 0.58 l.h-1.kg-1 for S-disopyramide after 100 mg t.d.s.).,Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761078/),[l] / [h·kg],0.39,18959,DB00280,Disopyramide
,1761078,clearance,There was enantioselective clearance of unbound disopyramide (0.39 l.h-1.kg-1 for R-disopyramide and 0.58 l.h-1.kg-1 for S-disopyramide after 100 mg t.d.s.).,Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761078/),[l] / [h·kg],0.58,18960,DB00280,Disopyramide
,1761078,renal clearance,"The renal clearance of S-MND was significantly higher than R-MND (0.29 and 0.19 l.h-1.kg-1, respectively, after 100 mg t.d.s.).",Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761078/),[l] / [h·kg],0.29,18961,DB00280,Disopyramide
,1761078,renal clearance,"The renal clearance of S-MND was significantly higher than R-MND (0.29 and 0.19 l.h-1.kg-1, respectively, after 100 mg t.d.s.).",Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761078/),[l] / [h·kg],0.19,18962,DB00280,Disopyramide
,7059444,elimination half-life,3 Mean elimination half-life (6.82 h) and bioavailability (79.8%) were consistent with findings from a previous study in young healthy volunteers.,Disopyramide pharmacokinetics during recovery from myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059444/),h,6.82,39537,DB00280,Disopyramide
,7059444,bioavailability,3 Mean elimination half-life (6.82 h) and bioavailability (79.8%) were consistent with findings from a previous study in young healthy volunteers.,Disopyramide pharmacokinetics during recovery from myocardial infarction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059444/),%,79.8,39538,DB00280,Disopyramide
,7059444,Volume of distribution,4 Volume of distribution was reduced by 25%: the mean +/- s.d. value was 0.61 +/- 0.17 l/kg.,Disopyramide pharmacokinetics during recovery from myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059444/),[l] / [kg],0.61,39539,DB00280,Disopyramide
,7059444,Total body clearance,Total body clearance was significantly reduced: the mean +/- s.d. value was 1.02 +/- 0.16 ml min-1 kg-1.,Disopyramide pharmacokinetics during recovery from myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059444/),[ml] / [kg·min],1.02,39540,DB00280,Disopyramide
,6840167,Maximum,"Maximum and minimum concentrations of the parent drug were 10.1 +/- 0.9 mumol/l (mean +/- SEM) and 5.7 +/- 0.5 mumol/l with CR tablets, and 10.2 +/- 0.5 mumol/l and 5.6 +/- 0.5 mumol/l with standard capsules.",Plasma concentration of disopyramide given as capsules and controlled release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840167/),[μM] / [l],10.1,41929,DB00280,Disopyramide
,6840167,Maximum,"Maximum and minimum concentrations of the parent drug were 10.1 +/- 0.9 mumol/l (mean +/- SEM) and 5.7 +/- 0.5 mumol/l with CR tablets, and 10.2 +/- 0.5 mumol/l and 5.6 +/- 0.5 mumol/l with standard capsules.",Plasma concentration of disopyramide given as capsules and controlled release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840167/),[μM] / [l],10.2,41930,DB00280,Disopyramide
,6840167,minimum concentrations,"Maximum and minimum concentrations of the parent drug were 10.1 +/- 0.9 mumol/l (mean +/- SEM) and 5.7 +/- 0.5 mumol/l with CR tablets, and 10.2 +/- 0.5 mumol/l and 5.6 +/- 0.5 mumol/l with standard capsules.",Plasma concentration of disopyramide given as capsules and controlled release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840167/),[μM] / [l],5.7,41931,DB00280,Disopyramide
,6840167,minimum concentrations,"Maximum and minimum concentrations of the parent drug were 10.1 +/- 0.9 mumol/l (mean +/- SEM) and 5.7 +/- 0.5 mumol/l with CR tablets, and 10.2 +/- 0.5 mumol/l and 5.6 +/- 0.5 mumol/l with standard capsules.",Plasma concentration of disopyramide given as capsules and controlled release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840167/),[μM] / [l],5.6,41932,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,101.1,46218,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,98.0,46219,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,94.4,46220,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,82.9,46221,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,4.4,46222,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,3.3,46223,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,4.7,46224,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,4.1,46225,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,6.5,46226,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,7.8,46227,DB00280,Disopyramide
,2229254,recoveries,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),%,2.4,46228,DB00280,Disopyramide
,2229254,lower detection limits,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),[ng] / [ml],40,46229,DB00280,Disopyramide
,2229254,lower detection limits,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),[ng] / [ml],80,46230,DB00280,Disopyramide
,2229254,lower detection limits,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),[ng] / [ml],100,46231,DB00280,Disopyramide
,2229254,lower detection limits,"This method was precise and sensitive: the mean recoveries from plasma at a concentration of 0.5 microgram/ml were 101.1% for (+)-DP, 98.0% for (-)-DP, 94.4% for (+)-MND and 82.9% for (-)-MND; the within- and between-day coefficients of variation at the same concentration were 4.4 and 3.3% for (+)-DP, 4.7 and 4.1% for (-)-DP, 6.5 and 4.1% for (+)-MND and 7.8 and 2.4% for (-)-MND for plasma; the lower detection limits were 40 ng/ml for (+)-DP, 80 ng/ml for (-)-DP, 100 ng/ml for (-)-MND and 200 ng/ml for (+)-MND, for 0.5 ml of plasma and 0.2 ml of urine.",Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229254/),[ng] / [ml],200,46232,DB00280,Disopyramide
,4024955,clearance,"The clearance in patients without myocardial infarction or congestive heart failure was 1.71 +/- 0.60 ml/min./kg (mean +/- S.D.), not significantly different from those who had either myocardial infarction, congestive heart failure or both.",Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024955/),[ml] / [·kg·min],1.71,52361,DB00280,Disopyramide
,4024955,Half-life,Half-life was 798 min.,Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024955/),min,798,52362,DB00280,Disopyramide
outside,4024955,steady state serum concentrations,"Twenty-six % of the steady state serum concentrations of disopyramide were outside the recommended therapeutic range (2-5 micrograms/ml), but no adverse haemodynamic effects were observed in any of the patients.",Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024955/),[μg] / [ml],2-5,52363,DB00280,Disopyramide
,6882625,final concentrations,Intravenous loading doses of 1.5 mg/kg followed by 0.7 mg/kg and then infusion of 0.3 mg kg-1h-1 resulted in final concentrations between 2.4 and 4.9 mg l.,Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882625/),l·mg,2.4 and 4.9,66212,DB00280,Disopyramide
,12067143,elimination rate constants (kes),"For DP, S(+)-DP and R(-)-DP, elimination rate constants (kes) were estimated as 0.0648, 0.0663 and 0.0691/h, respectively and the mean apparent volume of distribution (Vd/F) were estimated as 63.2, 54.1 and 71.6 l, respectively.","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),1/[h],0.0648,66538,DB00280,Disopyramide
,12067143,elimination rate constants (kes),"For DP, S(+)-DP and R(-)-DP, elimination rate constants (kes) were estimated as 0.0648, 0.0663 and 0.0691/h, respectively and the mean apparent volume of distribution (Vd/F) were estimated as 63.2, 54.1 and 71.6 l, respectively.","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),1/[h],0.0663,66539,DB00280,Disopyramide
,12067143,elimination rate constants (kes),"For DP, S(+)-DP and R(-)-DP, elimination rate constants (kes) were estimated as 0.0648, 0.0663 and 0.0691/h, respectively and the mean apparent volume of distribution (Vd/F) were estimated as 63.2, 54.1 and 71.6 l, respectively.","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),1/[h],0.0691,66540,DB00280,Disopyramide
,12067143,apparent volume of distribution (Vd/F),"For DP, S(+)-DP and R(-)-DP, elimination rate constants (kes) were estimated as 0.0648, 0.0663 and 0.0691/h, respectively and the mean apparent volume of distribution (Vd/F) were estimated as 63.2, 54.1 and 71.6 l, respectively.","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),l,63.2,66541,DB00280,Disopyramide
,12067143,apparent volume of distribution (Vd/F),"For DP, S(+)-DP and R(-)-DP, elimination rate constants (kes) were estimated as 0.0648, 0.0663 and 0.0691/h, respectively and the mean apparent volume of distribution (Vd/F) were estimated as 63.2, 54.1 and 71.6 l, respectively.","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),l,54.1,66542,DB00280,Disopyramide
,12067143,apparent volume of distribution (Vd/F),"For DP, S(+)-DP and R(-)-DP, elimination rate constants (kes) were estimated as 0.0648, 0.0663 and 0.0691/h, respectively and the mean apparent volume of distribution (Vd/F) were estimated as 63.2, 54.1 and 71.6 l, respectively.","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),l,71.6,66543,DB00280,Disopyramide
,12067143,binding ratio,"Unbound fractions of both DP enantiomers showed nonlinearity and the binding ratio of S(+)-DP was 0.84 +/- 0.07, which was higher than that of R(-)-DP [0.70 +/- 0.11 (p < 0.01)].","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),,0.84,66544,DB00280,Disopyramide
,12067143,binding ratio,"Unbound fractions of both DP enantiomers showed nonlinearity and the binding ratio of S(+)-DP was 0.84 +/- 0.07, which was higher than that of R(-)-DP [0.70 +/- 0.11 (p < 0.01)].","Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067143/),,0.70,66545,DB00280,Disopyramide
,3181285,elimination rate constant of,The elimination rate constant of unbound disopyramide was 0.094 h-1 and CLu/f (unbound clearance divided by bioavailability) was 245 ml/min.,Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment? ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181285/),1/[h],0.094,71906,DB00280,Disopyramide
,3181285,CLu/f (unbound clearance divided by bioavailability),The elimination rate constant of unbound disopyramide was 0.094 h-1 and CLu/f (unbound clearance divided by bioavailability) was 245 ml/min.,Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment? ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181285/),[ml] / [min],245,71907,DB00280,Disopyramide
,7069575,total body clearance of unbound drug,The mean +/-DS total body clearance of unbound drug in the eight subjects was 5.40 +/- 2.80 ml/min/kg.,The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069575/),[ml] / [kg·min],5.40,76906,DB00280,Disopyramide
,26349080,flow,"After evaporation, the residue was reconstituted in 200 μL of mobile phase (acetonitrile 85%:1% acetic acid 15%) and 50 μL was injected into the high-performance liquid chromatography column (X-Terra, RP8; flow: 1 mL/min).","Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ml] / [min],1,80730,DB00280,Disopyramide
,26349080,Plasma,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],10-106,80731,DB00280,Disopyramide
,26349080,Plasma,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],0.07-2.8,80732,DB00280,Disopyramide
,26349080,Plasma,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],1.2-36,80733,DB00280,Disopyramide
,26349080,DNox,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],0.5-45.4,80734,DB00280,Disopyramide
,2865105,association constant,"The association constant characterizing the interaction between plasma protein and the S(+)- and R(-)-enantiomers was 17.1 X 10(5) M-1, and 7.68 X respectively.",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),1/[M],17.1 X 10(5),90716,DB00280,Disopyramide
,2865105,association constant,"The association constant characterizing the interaction between plasma protein and the S(+)- and R(-)-enantiomers was 17.1 X 10(5) M-1, and 7.68 X respectively.",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),,7.68,90717,DB00280,Disopyramide
,2865105,unbound clearance,"The unbound clearance and half-life of S(+)-disopyramide averaged 604 ml/min and 3.67 hr, respectively, and differed from that of R(-)-disopyramide, which averaged 401 ml/min and 4.62 hr, respectively.",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),[ml] / [min],604,90718,DB00280,Disopyramide
,2865105,unbound clearance,"The unbound clearance and half-life of S(+)-disopyramide averaged 604 ml/min and 3.67 hr, respectively, and differed from that of R(-)-disopyramide, which averaged 401 ml/min and 4.62 hr, respectively.",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),[ml] / [min],401,90719,DB00280,Disopyramide
,2865105,unbound clearance,"The unbound clearance and half-life of S(+)-disopyramide averaged 604 ml/min and 3.67 hr, respectively, and differed from that of R(-)-disopyramide, which averaged 401 ml/min and 4.62 hr, respectively.",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),h,4.62,90720,DB00280,Disopyramide
,2865105,half-life,"The unbound clearance and half-life of S(+)-disopyramide averaged 604 ml/min and 3.67 hr, respectively, and differed from that of R(-)-disopyramide, which averaged 401 ml/min and 4.62 hr, respectively.",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),h,3.67,90721,DB00280,Disopyramide
,2865105,half-life,"The unbound clearance and half-life of S(+)-disopyramide averaged 604 ml/min and 3.67 hr, respectively, and differed from that of R(-)-disopyramide, which averaged 401 ml/min and 4.62 hr, respectively.",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),h,4.62,90722,DB00280,Disopyramide
,2865105,unbound renal clearance,"The unbound renal clearance of the S(+)- and R(-)-enantiomers averaged 338 and 182 ml/min, respectively (p = 0.05).",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),[ml] / [min],338,90723,DB00280,Disopyramide
,2865105,unbound renal clearance,"The unbound renal clearance of the S(+)- and R(-)-enantiomers averaged 338 and 182 ml/min, respectively (p = 0.05).",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),[ml] / [min],182,90724,DB00280,Disopyramide
,2865105,unbound steady-state volume of distribution,"The unbound steady-state volume of distribution of S(+)- and R(-)-disopyramide averaged 172 and 141 liters, respectively (p = 0.14).",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),l,172,90725,DB00280,Disopyramide
,2865105,unbound steady-state volume of distribution,"The unbound steady-state volume of distribution of S(+)- and R(-)-disopyramide averaged 172 and 141 liters, respectively (p = 0.14).",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),l,141,90726,DB00280,Disopyramide
,2865105,renal clearance,"The renal clearance of the mono-N-dealkylated metabolite of disopyramide following the administration of S(+)- and R(-)-disopyramide averaged 345 and 170 ml/min, respectively (p less than 0.05).",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),[ml] / [min],345,90727,DB00280,Disopyramide
,2865105,renal clearance,"The renal clearance of the mono-N-dealkylated metabolite of disopyramide following the administration of S(+)- and R(-)-disopyramide averaged 345 and 170 ml/min, respectively (p less than 0.05).",Stereoselective pharmacokinetics of disopyramide enantiomers in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865105/),[ml] / [min],170,90728,DB00280,Disopyramide
,1895553,plasma half life (T 1/2),"In CRF, the plasma half life (T 1/2) of DP was 5.25 to 22.42 hr (average is 12.45 hr) and that of MDP was 5.09 to 131.66 hr (average is 16.9 hr).",Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895553/),h,5.25 to 22.42,92050,DB00280,Disopyramide
,1895553,plasma half life (T 1/2),"In CRF, the plasma half life (T 1/2) of DP was 5.25 to 22.42 hr (average is 12.45 hr) and that of MDP was 5.09 to 131.66 hr (average is 16.9 hr).",Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895553/),h,12.45,92051,DB00280,Disopyramide
,1895553,plasma half life (T 1/2),"In CRF, the plasma half life (T 1/2) of DP was 5.25 to 22.42 hr (average is 12.45 hr) and that of MDP was 5.09 to 131.66 hr (average is 16.9 hr).",Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895553/),h,5.09 to 131.66,92052,DB00280,Disopyramide
,1895553,plasma half life (T 1/2),"In CRF, the plasma half life (T 1/2) of DP was 5.25 to 22.42 hr (average is 12.45 hr) and that of MDP was 5.09 to 131.66 hr (average is 16.9 hr).",Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895553/),h,16.9,92053,DB00280,Disopyramide
,1895553,T 1/2,"In normal controls, the T 1/2 of DP was 6.05 hr, but that of MDP could not be determined the available sensitivity of measurement.",Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895553/),h,6.05,92054,DB00280,Disopyramide
,1895553,T max,"T max was 3.11 hr at the total PC of DP and MDP, and C max was 2.48 g/ml on average.",Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895553/),h,3.11,92055,DB00280,Disopyramide
,1895553,C max,"T max was 3.11 hr at the total PC of DP and MDP, and C max was 2.48 g/ml on average.",Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895553/),[g] / [ml],2.48,92056,DB00280,Disopyramide
,3413032,metabolic clearance,"Approximately 50% of the administered disopyramide undergoes hepatic metabolism (metabolic clearance = 116.1 +/- 42.2 ml/min.), while the rest is excreted by the kidneys (renal clearance = 101.9 +/- 21.6 ml/min.).",Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413032/),[ml] / [min],116.1,100800,DB00280,Disopyramide
,3413032,renal clearance,"Approximately 50% of the administered disopyramide undergoes hepatic metabolism (metabolic clearance = 116.1 +/- 42.2 ml/min.), while the rest is excreted by the kidneys (renal clearance = 101.9 +/- 21.6 ml/min.).",Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413032/),[ml] / [min],101.9,100801,DB00280,Disopyramide
,3413032,Total renal excretion rate,Total renal excretion rate of disopyramide was 0.676 +/- 0.188 mumol/min. and 0.258 +/- 0.029 mumol/min.,Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413032/),[μM] / [min],0.676,100802,DB00280,Disopyramide
,3413032,Total renal excretion rate,Total renal excretion rate of disopyramide was 0.676 +/- 0.188 mumol/min. and 0.258 +/- 0.029 mumol/min.,Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413032/),[μM] / [min],0.258,100803,DB00280,Disopyramide
,7298249,elimination half-life,"The elimination half-life of disopyramide and N-deisopropyldisopyramide was close to 4 and 7 h, respectively.",Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7298249/),h,4,103372,DB00280,Disopyramide
,7298249,elimination half-life,"The elimination half-life of disopyramide and N-deisopropyldisopyramide was close to 4 and 7 h, respectively.",Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7298249/),h,7,103373,DB00280,Disopyramide
,4074615,total elimination clearance,The total elimination clearance was significantly (P less than 0.05) decreased in elderly non-smoking patients compared with young non-smoking subjects (1.54 +/- 0.33 vs 2.12 +/- 0.67 ml kg-1 min-1) (mean +/- s.d.).,The influence of age and smoking on the elimination of disopyramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[ml] / [kg·min],1.54,111657,DB00280,Disopyramide
,4074615,total elimination clearance,The total elimination clearance was significantly (P less than 0.05) decreased in elderly non-smoking patients compared with young non-smoking subjects (1.54 +/- 0.33 vs 2.12 +/- 0.67 ml kg-1 min-1) (mean +/- s.d.).,The influence of age and smoking on the elimination of disopyramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[ml] / [kg·min],2.12,111658,DB00280,Disopyramide
,4074615,total elimination clearance,"Smoking more than 20 cigarettes per day significantly (P less than 0.05) increased total elimination clearance in elderly (2.02 +/- 0.35 vs 1.54 +/- 0.33 ml kg-1 min-1), while no significant induction by tobacco was observed in young healthy persons.",The influence of age and smoking on the elimination of disopyramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[ml] / [kg·min],2.02,111659,DB00280,Disopyramide
,4074615,total elimination clearance,"Smoking more than 20 cigarettes per day significantly (P less than 0.05) increased total elimination clearance in elderly (2.02 +/- 0.35 vs 1.54 +/- 0.33 ml kg-1 min-1), while no significant induction by tobacco was observed in young healthy persons.",The influence of age and smoking on the elimination of disopyramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[ml] / [kg·min],1.54,111660,DB00280,Disopyramide
,4074615,volume of distribution (V),"However, the volume of distribution (V) was significantly (P less than 0.001) greater in the elderly patients (2.44 +/- 0.64 vs 1.16 +/- 0.15 1 kg-1).",The influence of age and smoking on the elimination of disopyramide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[1] / [kg],2.44,111661,DB00280,Disopyramide
,4074615,volume of distribution (V),"However, the volume of distribution (V) was significantly (P less than 0.001) greater in the elderly patients (2.44 +/- 0.64 vs 1.16 +/- 0.15 1 kg-1).",The influence of age and smoking on the elimination of disopyramide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[1] / [kg],1.16,111662,DB00280,Disopyramide
,4074615,Steady-state serum concentrations,Steady-state serum concentrations of the free drug were significantly (P less than 0.01) lower in the young volunteers (0.75 +/- 0.13 micrograms ml-1) than in the elderly (0.90 +/- 0.10 micrograms ml-1).,The influence of age and smoking on the elimination of disopyramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[μg] / [ml],0.75,111663,DB00280,Disopyramide
,4074615,Steady-state serum concentrations,Steady-state serum concentrations of the free drug were significantly (P less than 0.01) lower in the young volunteers (0.75 +/- 0.13 micrograms ml-1) than in the elderly (0.90 +/- 0.10 micrograms ml-1).,The influence of age and smoking on the elimination of disopyramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074615/),[μg] / [ml],0.90,111664,DB00280,Disopyramide
,262180,Retention times,"Retention times for the two compounds and the internal standard, p-chlorodisopyramide, were 3.4, 4.1, and 6.3 min, respectively.",Liquid chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/262180/),min,3.4,112225,DB00280,Disopyramide
,262180,Retention times,"Retention times for the two compounds and the internal standard, p-chlorodisopyramide, were 3.4, 4.1, and 6.3 min, respectively.",Liquid chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/262180/),min,4.1,112226,DB00280,Disopyramide
,262180,Retention times,"Retention times for the two compounds and the internal standard, p-chlorodisopyramide, were 3.4, 4.1, and 6.3 min, respectively.",Liquid chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/262180/),min,6.3,112227,DB00280,Disopyramide
,3772738,bioavailabilities,"Nonlinear binding of disopyramide to plasma proteins renders AUC an insensitive parameter for the discrimination of products with different extents of bioavailability; immediate-release products allowing bioavailabilities of 75 or 125% relative to the solution can generate AUCs 86 and 112%, respectively, of that from the solution.",The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772738/),%,75,113307,DB00280,Disopyramide
,3772738,bioavailabilities,"Nonlinear binding of disopyramide to plasma proteins renders AUC an insensitive parameter for the discrimination of products with different extents of bioavailability; immediate-release products allowing bioavailabilities of 75 or 125% relative to the solution can generate AUCs 86 and 112%, respectively, of that from the solution.",The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772738/),%,125,113308,DB00280,Disopyramide
,3772738,bioavailability,"Nonlinear binding, furthermore, leads to a tendency for AUC to overestimate the bioavailability of slower release products in single-dose studies; if AUC were the index of bioavailability, products permitting the same bioavailability as the solution but releasing over 12 hr could appear to allow 114% relative bioavailability.",The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772738/),%,114,113309,DB00280,Disopyramide
,3772738,apparent relative bioavailability,"Moreover, in some situations the bias arising from the insensitivity of AUC to product differences can be reinforced by the dependence of AUC on release rate; an apparent relative bioavailability of 80% can be achieved by a 12-hr release product allowing a true relative bioavailability of a mere 58%.",The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772738/),%,80,113310,DB00280,Disopyramide
,3772738,true relative bioavailability,"Moreover, in some situations the bias arising from the insensitivity of AUC to product differences can be reinforced by the dependence of AUC on release rate; an apparent relative bioavailability of 80% can be achieved by a 12-hr release product allowing a true relative bioavailability of a mere 58%.",The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772738/),%,58,113311,DB00280,Disopyramide
,6199608,cardiac output,"In the low-dose group, there was a fall in cardiac output which reached statistical significance at 300 min [from 3.4 +/- 0.4 (SD) to 2.7 +/- 0.7 L/min; p less than 0.05, analysis of variance (ANOVA)].",Pharmacokinetic-hemodynamic studies of disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [min],3.4,113766,DB00280,Disopyramide
,6199608,cardiac output,"In the low-dose group, there was a fall in cardiac output which reached statistical significance at 300 min [from 3.4 +/- 0.4 (SD) to 2.7 +/- 0.7 L/min; p less than 0.05, analysis of variance (ANOVA)].",Pharmacokinetic-hemodynamic studies of disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [min],2.7,113767,DB00280,Disopyramide
,6199608,cardiac output,"In the high-dose group, there also was a fall in cardiac output (from 4.6 +/- 1.4 to 3.0 +/- 0.4 L/min; p less than 0.01, ANOVA), and this was associated with a rise in total peripheral resistance (from 39 +/- 11 to 58 +/- 9 units; p less than 0.01).",Pharmacokinetic-hemodynamic studies of disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [min],4.6,113768,DB00280,Disopyramide
,6199608,cardiac output,"In the high-dose group, there also was a fall in cardiac output (from 4.6 +/- 1.4 to 3.0 +/- 0.4 L/min; p less than 0.01, ANOVA), and this was associated with a rise in total peripheral resistance (from 39 +/- 11 to 58 +/- 9 units; p less than 0.01).",Pharmacokinetic-hemodynamic studies of disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [min],3.0,113769,DB00280,Disopyramide
,6199608,total peripheral resistance,"In the high-dose group, there also was a fall in cardiac output (from 4.6 +/- 1.4 to 3.0 +/- 0.4 L/min; p less than 0.01, ANOVA), and this was associated with a rise in total peripheral resistance (from 39 +/- 11 to 58 +/- 9 units; p less than 0.01).",Pharmacokinetic-hemodynamic studies of disopyramide. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),units,39,113770,DB00280,Disopyramide
,6199608,total peripheral resistance,"In the high-dose group, there also was a fall in cardiac output (from 4.6 +/- 1.4 to 3.0 +/- 0.4 L/min; p less than 0.01, ANOVA), and this was associated with a rise in total peripheral resistance (from 39 +/- 11 to 58 +/- 9 units; p less than 0.01).",Pharmacokinetic-hemodynamic studies of disopyramide. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),units,58,113771,DB00280,Disopyramide
,6199608,Peak total venous DP concentrations,"Peak total venous DP concentrations were 3.0 +/- 0.2 and 7.5 +/- 1.0 micrograms/ml for the low- and high-dose groups, respectively, and were achieved at the end of the load infusion.",Pharmacokinetic-hemodynamic studies of disopyramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[μg] / [ml],3.0,113772,DB00280,Disopyramide
,6199608,Peak total venous DP concentrations,"Peak total venous DP concentrations were 3.0 +/- 0.2 and 7.5 +/- 1.0 micrograms/ml for the low- and high-dose groups, respectively, and were achieved at the end of the load infusion.",Pharmacokinetic-hemodynamic studies of disopyramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[μg] / [ml],7.5,113773,DB00280,Disopyramide
,6199608,free fraction,The free fraction of DP was not dependent on total venous DP concentration and approximated 0.66.,Pharmacokinetic-hemodynamic studies of disopyramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),,0.66,113774,DB00280,Disopyramide
,6199608,Elimination half-life,"Elimination half-life, clearance, and apparent volume of distribution were 3.91 +/- 0.53 h, 0.39 +/- 0.02 L/kg/h, and 2.22 +/- 0.32 L/kg, respectively, for the low-dose group and 3.67 +/- 0.91 h, 0.36 +/- 0.06 L/kg/h, and 1.84 +/- 0.29 L/kg, respectively, for the high-dose group.",Pharmacokinetic-hemodynamic studies of disopyramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),h,3.91,113775,DB00280,Disopyramide
,6199608,clearance,"Elimination half-life, clearance, and apparent volume of distribution were 3.91 +/- 0.53 h, 0.39 +/- 0.02 L/kg/h, and 2.22 +/- 0.32 L/kg, respectively, for the low-dose group and 3.67 +/- 0.91 h, 0.36 +/- 0.06 L/kg/h, and 1.84 +/- 0.29 L/kg, respectively, for the high-dose group.",Pharmacokinetic-hemodynamic studies of disopyramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [h·kg],0.39,113776,DB00280,Disopyramide
,6199608,clearance,"Elimination half-life, clearance, and apparent volume of distribution were 3.91 +/- 0.53 h, 0.39 +/- 0.02 L/kg/h, and 2.22 +/- 0.32 L/kg, respectively, for the low-dose group and 3.67 +/- 0.91 h, 0.36 +/- 0.06 L/kg/h, and 1.84 +/- 0.29 L/kg, respectively, for the high-dose group.",Pharmacokinetic-hemodynamic studies of disopyramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),h,3.67,113777,DB00280,Disopyramide
,6199608,clearance,"Elimination half-life, clearance, and apparent volume of distribution were 3.91 +/- 0.53 h, 0.39 +/- 0.02 L/kg/h, and 2.22 +/- 0.32 L/kg, respectively, for the low-dose group and 3.67 +/- 0.91 h, 0.36 +/- 0.06 L/kg/h, and 1.84 +/- 0.29 L/kg, respectively, for the high-dose group.",Pharmacokinetic-hemodynamic studies of disopyramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [h·kg],0.36,113778,DB00280,Disopyramide
,6199608,apparent volume of distribution,"Elimination half-life, clearance, and apparent volume of distribution were 3.91 +/- 0.53 h, 0.39 +/- 0.02 L/kg/h, and 2.22 +/- 0.32 L/kg, respectively, for the low-dose group and 3.67 +/- 0.91 h, 0.36 +/- 0.06 L/kg/h, and 1.84 +/- 0.29 L/kg, respectively, for the high-dose group.",Pharmacokinetic-hemodynamic studies of disopyramide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [kg],2.22,113779,DB00280,Disopyramide
,6199608,apparent volume of distribution,"Elimination half-life, clearance, and apparent volume of distribution were 3.91 +/- 0.53 h, 0.39 +/- 0.02 L/kg/h, and 2.22 +/- 0.32 L/kg, respectively, for the low-dose group and 3.67 +/- 0.91 h, 0.36 +/- 0.06 L/kg/h, and 1.84 +/- 0.29 L/kg, respectively, for the high-dose group.",Pharmacokinetic-hemodynamic studies of disopyramide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6199608/),[l] / [kg],1.84,113780,DB00280,Disopyramide
,8330460,peak-to-trough ratios,"Comparison of total to unbound drug showed that peak-to-trough ratios during steady state were smaller (1.45 versus 2.39; p < 0.001), elimination half-life was longer (12.1 versus 4.5 hours; p < 0.001), and the time to achieve 50% of steady-state levels during drug accumulation was shorter (8.1 versus 4.3 hours; p < 0.05).",Immediate- versus controlled-release disopyramide: importance of saturable binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),,1.45,121072,DB00280,Disopyramide
,8330460,peak-to-trough ratios,"Comparison of total to unbound drug showed that peak-to-trough ratios during steady state were smaller (1.45 versus 2.39; p < 0.001), elimination half-life was longer (12.1 versus 4.5 hours; p < 0.001), and the time to achieve 50% of steady-state levels during drug accumulation was shorter (8.1 versus 4.3 hours; p < 0.05).",Immediate- versus controlled-release disopyramide: importance of saturable binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),,2.39,121073,DB00280,Disopyramide
,8330460,elimination half-life,"Comparison of total to unbound drug showed that peak-to-trough ratios during steady state were smaller (1.45 versus 2.39; p < 0.001), elimination half-life was longer (12.1 versus 4.5 hours; p < 0.001), and the time to achieve 50% of steady-state levels during drug accumulation was shorter (8.1 versus 4.3 hours; p < 0.05).",Immediate- versus controlled-release disopyramide: importance of saturable binding. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),h,12.1,121074,DB00280,Disopyramide
,8330460,elimination half-life,"Comparison of total to unbound drug showed that peak-to-trough ratios during steady state were smaller (1.45 versus 2.39; p < 0.001), elimination half-life was longer (12.1 versus 4.5 hours; p < 0.001), and the time to achieve 50% of steady-state levels during drug accumulation was shorter (8.1 versus 4.3 hours; p < 0.05).",Immediate- versus controlled-release disopyramide: importance of saturable binding. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),h,4.5,121075,DB00280,Disopyramide
,8330460,time to achieve 50% of steady-state levels,"Comparison of total to unbound drug showed that peak-to-trough ratios during steady state were smaller (1.45 versus 2.39; p < 0.001), elimination half-life was longer (12.1 versus 4.5 hours; p < 0.001), and the time to achieve 50% of steady-state levels during drug accumulation was shorter (8.1 versus 4.3 hours; p < 0.05).",Immediate- versus controlled-release disopyramide: importance of saturable binding. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),h,8.1,121076,DB00280,Disopyramide
,8330460,time to achieve 50% of steady-state levels,"Comparison of total to unbound drug showed that peak-to-trough ratios during steady state were smaller (1.45 versus 2.39; p < 0.001), elimination half-life was longer (12.1 versus 4.5 hours; p < 0.001), and the time to achieve 50% of steady-state levels during drug accumulation was shorter (8.1 versus 4.3 hours; p < 0.05).",Immediate- versus controlled-release disopyramide: importance of saturable binding. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),h,4.3,121077,DB00280,Disopyramide
,8330460,peak plasma concentrations,Comparison of IR and CR disopyramide showed that unbound drug levels for CR disopyramide revealed lower peak plasma concentrations (0.75 versus 0.96 micrograms/ml) and peak-to-trough ratios (1.83 versus 2.31; p < 0.001).,Immediate- versus controlled-release disopyramide: importance of saturable binding. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),[μg] / [ml],0.75,121078,DB00280,Disopyramide
,8330460,peak plasma concentrations,Comparison of IR and CR disopyramide showed that unbound drug levels for CR disopyramide revealed lower peak plasma concentrations (0.75 versus 0.96 micrograms/ml) and peak-to-trough ratios (1.83 versus 2.31; p < 0.001).,Immediate- versus controlled-release disopyramide: importance of saturable binding. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),[μg] / [ml],0.96,121079,DB00280,Disopyramide
,8330460,peak-to-trough ratios,Comparison of IR and CR disopyramide showed that unbound drug levels for CR disopyramide revealed lower peak plasma concentrations (0.75 versus 0.96 micrograms/ml) and peak-to-trough ratios (1.83 versus 2.31; p < 0.001).,Immediate- versus controlled-release disopyramide: importance of saturable binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),,1.83,121080,DB00280,Disopyramide
,8330460,peak-to-trough ratios,Comparison of IR and CR disopyramide showed that unbound drug levels for CR disopyramide revealed lower peak plasma concentrations (0.75 versus 0.96 micrograms/ml) and peak-to-trough ratios (1.83 versus 2.31; p < 0.001).,Immediate- versus controlled-release disopyramide: importance of saturable binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330460/),,2.31,121081,DB00280,Disopyramide
,2907466,unbound clearance,"The mean unbound clearance of (R)-(-)-DP and (S)-(+)-DP were 8.59 and 14.9 ml/min/kg, respectively (p = 0.003).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],8.59,130215,DB00280,Disopyramide
,2907466,unbound clearance,"The mean unbound clearance of (R)-(-)-DP and (S)-(+)-DP were 8.59 and 14.9 ml/min/kg, respectively (p = 0.003).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],14.9,130216,DB00280,Disopyramide
,2907466,unbound renal clearance,"The mean unbound renal clearance of (R)-(-)-DP and (S)-(+)-DP were 6.26 and 8.75 ml/min/kg, respectively (p = 0.025).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],6.26,130217,DB00280,Disopyramide
,2907466,unbound renal clearance,"The mean unbound renal clearance of (R)-(-)-DP and (S)-(+)-DP were 6.26 and 8.75 ml/min/kg, respectively (p = 0.025).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],8.75,130218,DB00280,Disopyramide
,2907466,nonrenal clearance,"The nonrenal clearance, i.e. hepatic metabolic clearance, of (R)-(-)-DP and (S)-(+)-DP averaged 2.32 and 6.19 ml/min/kg, respectively (p = 0.002).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],2.32,130219,DB00280,Disopyramide
,2907466,nonrenal clearance,"The nonrenal clearance, i.e. hepatic metabolic clearance, of (R)-(-)-DP and (S)-(+)-DP averaged 2.32 and 6.19 ml/min/kg, respectively (p = 0.002).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],6.19,130220,DB00280,Disopyramide
,2907466,hepatic metabolic clearance,"The nonrenal clearance, i.e. hepatic metabolic clearance, of (R)-(-)-DP and (S)-(+)-DP averaged 2.32 and 6.19 ml/min/kg, respectively (p = 0.002).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],2.32,130221,DB00280,Disopyramide
,2907466,hepatic metabolic clearance,"The nonrenal clearance, i.e. hepatic metabolic clearance, of (R)-(-)-DP and (S)-(+)-DP averaged 2.32 and 6.19 ml/min/kg, respectively (p = 0.002).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],6.19,130222,DB00280,Disopyramide
,2907466,unbound volume of distribution,"The mean unbound volume of distribution of (R)-(-)- and (S)-(+)-DP were 225 and 381 liters, respectively (p = 0.023).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),l,225,130223,DB00280,Disopyramide
,2907466,unbound volume of distribution,"The mean unbound volume of distribution of (R)-(-)- and (S)-(+)-DP were 225 and 381 liters, respectively (p = 0.023).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),l,381,130224,DB00280,Disopyramide
,2907466,half-life,"The half-life of (R)-(-)-DP and (S)-(+)-DP averaged 4.17 and 3.91 hr, respectively (p = 0.21).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),h,4.17,130225,DB00280,Disopyramide
,2907466,half-life,"The half-life of (R)-(-)-DP and (S)-(+)-DP averaged 4.17 and 3.91 hr, respectively (p = 0.21).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),h,3.91,130226,DB00280,Disopyramide
,2907466,unbound renal clearance,"The mean unbound renal clearance of (R)-(-)- and (S)-(+)-mono-N-dealkylated disopyramide (MND) were 3.21 and 7.02 ml/min/kg, respectively (p less than 0.001).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],3.21,130227,DB00280,Disopyramide
,2907466,unbound renal clearance,"The mean unbound renal clearance of (R)-(-)- and (S)-(+)-mono-N-dealkylated disopyramide (MND) were 3.21 and 7.02 ml/min/kg, respectively (p less than 0.001).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),[ml] / [kg·min],7.02,130228,DB00280,Disopyramide
,2907466,unbound fraction at steady state,"The unbound fraction at steady state of (R)-(-)-DP and (S)-(+)-DP averaged 12.5 and 7.5%, respectively (p = 0.002).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),%,12.5,130229,DB00280,Disopyramide
,2907466,unbound fraction at steady state,"The unbound fraction at steady state of (R)-(-)-DP and (S)-(+)-DP averaged 12.5 and 7.5%, respectively (p = 0.002).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),%,7.5,130230,DB00280,Disopyramide
,2907466,unbound fraction at steady state,"The unbound fraction at steady state of (R)-(-)-DP and (S)-(+)-MND averaged 62.6 and 60.5%, respectively (p = 0.36).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),%,62.6,130231,DB00280,Disopyramide
,2907466,unbound fraction at steady state,"The unbound fraction at steady state of (R)-(-)-DP and (S)-(+)-MND averaged 62.6 and 60.5%, respectively (p = 0.36).",Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907466/),%,60.5,130232,DB00280,Disopyramide
,7407335,oral availability,"The results from the cross-over study showed [13C, 15N]disopyramide to have an oral availability of 4.9 +/- 0.9% (by comparing areas under the plasma concentration versus time curves).",The absorption of disopyramide in animals determined using a stable isotope co-administration technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7407335/),%,4.9,130759,DB00280,Disopyramide
,7407335,bioavailability,The bioavailability was estimated to be 5.7 +/- 0.3% comparing totals excreted in urine over 48 h.,The absorption of disopyramide in animals determined using a stable isotope co-administration technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7407335/),%,5.7,130760,DB00280,Disopyramide
,7407335,bioavailability,The bioavailability of the oral dose was calculated as 8.2 +/- 2.5% (comparing areas under plasma concentration versus time curves) and 9.3 +/- 3.0% (comparing totals excreted in urine) after co-administration.,The absorption of disopyramide in animals determined using a stable isotope co-administration technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7407335/),%,8.2,130761,DB00280,Disopyramide
,7407335,bioavailability,The bioavailability of the oral dose was calculated as 8.2 +/- 2.5% (comparing areas under plasma concentration versus time curves) and 9.3 +/- 3.0% (comparing totals excreted in urine) after co-administration.,The absorption of disopyramide in animals determined using a stable isotope co-administration technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7407335/),%,9.3,130762,DB00280,Disopyramide
,2482304,total plasma clearance,"During the racemic period, the mean total plasma clearance, expressed as CL/F, of S(+) DP (114.6 ml/min), was significantly lower than that of R(-) DP (157 ml/min), (P less than .001).","Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2482304/),[ml] / [min],114.6,133375,DB00280,Disopyramide
,2482304,total plasma clearance,"During the racemic period, the mean total plasma clearance, expressed as CL/F, of S(+) DP (114.6 ml/min), was significantly lower than that of R(-) DP (157 ml/min), (P less than .001).","Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2482304/),[ml] / [min],157,133376,DB00280,Disopyramide
,2482304,CL/F,"During the racemic period, the mean total plasma clearance, expressed as CL/F, of S(+) DP (114.6 ml/min), was significantly lower than that of R(-) DP (157 ml/min), (P less than .001).","Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2482304/),[ml] / [min],114.6,133377,DB00280,Disopyramide
,2482304,CL/F,"During the racemic period, the mean total plasma clearance, expressed as CL/F, of S(+) DP (114.6 ml/min), was significantly lower than that of R(-) DP (157 ml/min), (P less than .001).","Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2482304/),[ml] / [min],157,133378,DB00280,Disopyramide
,2482304,total plasma clearance,"The mean total plasma clearance of R(-) DP, during the levorotatory period (163 ml/min), did not differ from the respective value determined during the racemic period (P = .32).","Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2482304/),[ml] / [min],163,133379,DB00280,Disopyramide
,6160331,clearance,The clearance of d-disopyramide (15.4 +/- 5.10 ml/min/kg) was significantly greater than that of the l-isomer (9.45 +/- 2.52 ml/min/kg) (p < 0.001).,The stereoselective disposition of disopyramide in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160331/),[ml] / [kg·min],15.4,138304,DB00280,Disopyramide
,6160331,clearance,The clearance of d-disopyramide (15.4 +/- 5.10 ml/min/kg) was significantly greater than that of the l-isomer (9.45 +/- 2.52 ml/min/kg) (p < 0.001).,The stereoselective disposition of disopyramide in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160331/),[ml] / [kg·min],9.45,138305,DB00280,Disopyramide
,6160331,steady-state volume of distribution,The steady-state volume of distribution of the three compounds was similar (approximately 1.4 liters/kg).,The stereoselective disposition of disopyramide in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160331/),[l] / [kg],1.4,138306,DB00280,Disopyramide
,6160331,elimination half-life,"The elimination half-life reflected differences in clearance, being 76.4 +/- 7.30 min for d-disopyramide, 112 +/- 23.4 min for 1-disopyramide, and 97.2 +/- 15.1 min for d,1-disopyramide.",The stereoselective disposition of disopyramide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160331/),min,76.4,138307,DB00280,Disopyramide
,6160331,elimination half-life,"The elimination half-life reflected differences in clearance, being 76.4 +/- 7.30 min for d-disopyramide, 112 +/- 23.4 min for 1-disopyramide, and 97.2 +/- 15.1 min for d,1-disopyramide.",The stereoselective disposition of disopyramide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160331/),min,112,138308,DB00280,Disopyramide
,6160331,elimination half-life,"The elimination half-life reflected differences in clearance, being 76.4 +/- 7.30 min for d-disopyramide, 112 +/- 23.4 min for 1-disopyramide, and 97.2 +/- 15.1 min for d,1-disopyramide.",The stereoselective disposition of disopyramide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160331/),min,97.2,138309,DB00280,Disopyramide
,6124395,maximum plasma concentration (Cmax),"In rats, after oral administration of (S)-(+)-DP phosphate salt at a dose of 38.8 mg of DP free base per kg, the mean maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) were 1.43 micrograms/ml and 4.47 micrograms .",Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124395/),[μg] / [ml],1.43,143967,DB00280,Disopyramide
,6124395,area under the plasma concentration-time curve (AUC),"In rats, after oral administration of (S)-(+)-DP phosphate salt at a dose of 38.8 mg of DP free base per kg, the mean maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) were 1.43 micrograms/ml and 4.47 micrograms .",Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124395/),μg,4.47,143968,DB00280,Disopyramide
,6124395,recoveries,Similar recoveries (approximately 55% of the dose) of DP and its metabolites in the urine and bile of rats were obtained after administration of the individual (S)-(+)- and (R)-(-)-enantiomers of DP.,Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124395/),,55,143969,DB00280,Disopyramide
,6124395,Cmax,The mean values of Cmax and AUC after a 15-mg/kg oral dose of (S)-(+)-DP were 1.32 micrograms/ml and 4.07 micrograms .,Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124395/),[μg] / [ml],1.32,143970,DB00280,Disopyramide
,6124395,AUC,The mean values of Cmax and AUC after a 15-mg/kg oral dose of (S)-(+)-DP were 1.32 micrograms/ml and 4.07 micrograms .,Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124395/),μg,4.07,143971,DB00280,Disopyramide
,3987785,peak serum concentrations,"The peak serum concentrations of disopyramide after oral dosing in Studies I and II were 2.6 +/- 1.2 (SEM) and 6.4 +/- 1.9 microgram/ml, respectively (p less than 0.05), the peak times 3.29 +/- 1.22 and 1.21 +/- 0.39 h (N.S.) and the AUCINF 38.0 +/- 7.7 and 60.7 +/- 9.9 micrograms . h . ml-1 (p less than 0.05).",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),[μg] / [ml],2.6,162994,DB00280,Disopyramide
,3987785,peak serum concentrations,"The peak serum concentrations of disopyramide after oral dosing in Studies I and II were 2.6 +/- 1.2 (SEM) and 6.4 +/- 1.9 microgram/ml, respectively (p less than 0.05), the peak times 3.29 +/- 1.22 and 1.21 +/- 0.39 h (N.S.) and the AUCINF 38.0 +/- 7.7 and 60.7 +/- 9.9 micrograms . h . ml-1 (p less than 0.05).",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),[μg] / [ml],6.4,162995,DB00280,Disopyramide
,3987785,peak times,"The peak serum concentrations of disopyramide after oral dosing in Studies I and II were 2.6 +/- 1.2 (SEM) and 6.4 +/- 1.9 microgram/ml, respectively (p less than 0.05), the peak times 3.29 +/- 1.22 and 1.21 +/- 0.39 h (N.S.) and the AUCINF 38.0 +/- 7.7 and 60.7 +/- 9.9 micrograms . h . ml-1 (p less than 0.05).",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),h,3.29,162996,DB00280,Disopyramide
,3987785,peak times,"The peak serum concentrations of disopyramide after oral dosing in Studies I and II were 2.6 +/- 1.2 (SEM) and 6.4 +/- 1.9 microgram/ml, respectively (p less than 0.05), the peak times 3.29 +/- 1.22 and 1.21 +/- 0.39 h (N.S.) and the AUCINF 38.0 +/- 7.7 and 60.7 +/- 9.9 micrograms . h . ml-1 (p less than 0.05).",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),h,1.21,162997,DB00280,Disopyramide
,3987785,AUCINF,"The peak serum concentrations of disopyramide after oral dosing in Studies I and II were 2.6 +/- 1.2 (SEM) and 6.4 +/- 1.9 microgram/ml, respectively (p less than 0.05), the peak times 3.29 +/- 1.22 and 1.21 +/- 0.39 h (N.S.) and the AUCINF 38.0 +/- 7.7 and 60.7 +/- 9.9 micrograms . h . ml-1 (p less than 0.05).",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),[h·μg] / [ml],38.0,162998,DB00280,Disopyramide
,3987785,AUCINF,"The peak serum concentrations of disopyramide after oral dosing in Studies I and II were 2.6 +/- 1.2 (SEM) and 6.4 +/- 1.9 microgram/ml, respectively (p less than 0.05), the peak times 3.29 +/- 1.22 and 1.21 +/- 0.39 h (N.S.) and the AUCINF 38.0 +/- 7.7 and 60.7 +/- 9.9 micrograms . h . ml-1 (p less than 0.05).",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),[h·μg] / [ml],60.7,162999,DB00280,Disopyramide
,3987785,recovery,"The recovery of disopyramide in urine over 3 days averaged 46% and 47% of dose, and that of mono-N-dealkyl disopyramide 22% and 16% of the dose, respectively.",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),%,46,163000,DB00280,Disopyramide
,3987785,recovery,"The recovery of disopyramide in urine over 3 days averaged 46% and 47% of dose, and that of mono-N-dealkyl disopyramide 22% and 16% of the dose, respectively.",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),%,47,163001,DB00280,Disopyramide
,3987785,recovery,"The recovery of disopyramide in urine over 3 days averaged 46% and 47% of dose, and that of mono-N-dealkyl disopyramide 22% and 16% of the dose, respectively.",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),%,22,163002,DB00280,Disopyramide
,3987785,recovery,"The recovery of disopyramide in urine over 3 days averaged 46% and 47% of dose, and that of mono-N-dealkyl disopyramide 22% and 16% of the dose, respectively.",Disopyramide pharmacokinetics in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987785/),%,16,163003,DB00280,Disopyramide
,24277185,limit of sensitivity,The method is highly reproducible and has a limit of sensitivity of 2.5 ng/ml from a 2.0 ml serum sample.,High pressure liquid chromatographic analysis of metoclopramide in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277185/),[ng] / [ml],2.5,164725,DB00280,Disopyramide
,30173081,m,"The most sensitive signals by multiple reaction monitoring (MRM) showed at m/z 340.2 → 239.2 and 298.2 → 239.2 with same fragment ion for disopyramide and mono-isopropyl-disopyramide, respectively.","A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173081/),,340.2,169229,DB00280,Disopyramide
,30173081,m,"The most sensitive signals by multiple reaction monitoring (MRM) showed at m/z 340.2 → 239.2 and 298.2 → 239.2 with same fragment ion for disopyramide and mono-isopropyl-disopyramide, respectively.","A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173081/),,298.,169230,DB00280,Disopyramide
,3440098,Cp 21st day,The disposition of orally administered disopyramide was studied in a population of smokers (n = 6) and non-smokers (n = 8) before and during phenobarbitone treatment (100 mg daily for 21 days; Cp 21st day = 13.9 +/- 2.0 micrograms ml-1).,Disopyramide pharmacokinetics and metabolism: effect of inducers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[μg] / [ml],13.9,180959,DB00280,Disopyramide
,3440098,half-lives,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),h,6.48,180960,DB00280,Disopyramide
,3440098,half-lives,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),h,6.66,180961,DB00280,Disopyramide
,3440098,apparent total body clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.100,180962,DB00280,Disopyramide
,3440098,apparent total body clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.117,180963,DB00280,Disopyramide
,3440098,renal clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.043,180964,DB00280,Disopyramide
,3440098,renal clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.057,180965,DB00280,Disopyramide
,3440098,apparent intrinsic metabolic clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.057,180966,DB00280,Disopyramide
,3440098,apparent intrinsic metabolic clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.060,180967,DB00280,Disopyramide
,3440098,AUC,"4. Phenobarbitone treatment of non-smokers resulted in an increase in the AUC of the active metabolite N-despropyl disopyramide (MND), but not significantly (3.8 +/- 1.6 vs 4.1 +/- 2.3 micrograms ml-1 h).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[h·μg] / [ml],3.8,180968,DB00280,Disopyramide
,3440098,AUC,"4. Phenobarbitone treatment of non-smokers resulted in an increase in the AUC of the active metabolite N-despropyl disopyramide (MND), but not significantly (3.8 +/- 1.6 vs 4.1 +/- 2.3 micrograms ml-1 h).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[h·μg] / [ml],4.1,180969,DB00280,Disopyramide
,3440098,percent,"5. The percent of administered dose recovered in urine as disopyramide in non-smokers was significantly decreased upon phenobarbitone treatment (43 +/- 6% vs 25 +/- 5%), whereas the percent of dose recovered as MND increased significantly in this group (25 +/- 6% vs 31 +/- 5%).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),%,43,180970,DB00280,Disopyramide
,3440098,percent,"5. The percent of administered dose recovered in urine as disopyramide in non-smokers was significantly decreased upon phenobarbitone treatment (43 +/- 6% vs 25 +/- 5%), whereas the percent of dose recovered as MND increased significantly in this group (25 +/- 6% vs 31 +/- 5%).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),%,25,180971,DB00280,Disopyramide
,7215416,biological half life of rapid distribution (T1/2 alpha),"The biological half life of rapid distribution (T1/2 alpha) and of elimination (T1/2 beta) were increased (11.1 +/- 4.4 min and 9.7 +/- 4.2 h, respectively).",Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215416/),min,11.1,184022,DB00280,Disopyramide
,7215416,Total body clearance (Clt),"Total body clearance (Clt) was decreased (0.467 +/- 0.215 ml . min-1 . kg-1), and the volume of distribution (Vd) was slightly reduced (0.610 +/- 0.1361 . kg-1), probably due to the lower cardiac index.",Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215416/),[ml] / [kg·min],0.467,184023,DB00280,Disopyramide
,7215416,volume of distribution (Vd),"Total body clearance (Clt) was decreased (0.467 +/- 0.215 ml . min-1 . kg-1), and the volume of distribution (Vd) was slightly reduced (0.610 +/- 0.1361 . kg-1), probably due to the lower cardiac index.",Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215416/),1/[kg],0.610,184024,DB00280,Disopyramide
,7215416,time of peak serum concentration,"After oral administration, the time of peak serum concentration was increased (139 +/- 89 min), and the mean peak serum concentration (2.4 +/- 0.8% dose . 1-1) was also higher than reported in normal subjects.",Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215416/),min,139,184025,DB00280,Disopyramide
,7215416,peak serum concentration,"After oral administration, the time of peak serum concentration was increased (139 +/- 89 min), and the mean peak serum concentration (2.4 +/- 0.8% dose . 1-1) was also higher than reported in normal subjects.",Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215416/),%·dose,2.4,184026,DB00280,Disopyramide
,7215416,bioavailability,"Comparison of the areas under the concentration versus time curves after intravenous and oral administration (AUC i. v. and AUC oral) showed that DP was almost completely absorbed, its bioavailability being 97.5 +/- 15.0%.",Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215416/),%,97.5,184027,DB00280,Disopyramide
,8450476,Km,"The high- and low-affinity sites gave the mean (+/- S.D.) Km of 5.7 +/- 2.8 and 724.7 +/- 427.4 microM, and Vmax of 2.90 +/- 1.17 and 18.20 +/- 8.84 nmol/hr/mg protein, respectively.",A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),μM,5.7,186146,DB00280,Disopyramide
,8450476,Km,"The high- and low-affinity sites gave the mean (+/- S.D.) Km of 5.7 +/- 2.8 and 724.7 +/- 427.4 microM, and Vmax of 2.90 +/- 1.17 and 18.20 +/- 8.84 nmol/hr/mg protein, respectively.",A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),μM,724.7,186147,DB00280,Disopyramide
,8450476,Vmax,"The high- and low-affinity sites gave the mean (+/- S.D.) Km of 5.7 +/- 2.8 and 724.7 +/- 427.4 microM, and Vmax of 2.90 +/- 1.17 and 18.20 +/- 8.84 nmol/hr/mg protein, respectively.",A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),[nM] / [h·mg],2.90,186148,DB00280,Disopyramide
,8450476,Vmax,"The high- and low-affinity sites gave the mean (+/- S.D.) Km of 5.7 +/- 2.8 and 724.7 +/- 427.4 microM, and Vmax of 2.90 +/- 1.17 and 18.20 +/- 8.84 nmol/hr/mg protein, respectively.",A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),[nM] / [h·mg],18.20,186149,DB00280,Disopyramide
,8450476,"intrinsic clearance (i.e., Vmax/Km)","Because the mean intrinsic clearance (i.e., Vmax/Km) for the high-affinity site (i.e., 0.79 +/- 0.69 ml/hr/mg protein) was about 30 times greater than that for the low-affinity site (i.e., 0.03 +/- 0.01 ml/hr/mg protein), the high-affinity site was considered more important in the DP metabolism at its therapeutic concentrations (i.e., 2-5 micrograms/ml or 5-14 microM).",A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),[ml] / [h·mg],0.79,186150,DB00280,Disopyramide
,8450476,"intrinsic clearance (i.e., Vmax/Km)","Because the mean intrinsic clearance (i.e., Vmax/Km) for the high-affinity site (i.e., 0.79 +/- 0.69 ml/hr/mg protein) was about 30 times greater than that for the low-affinity site (i.e., 0.03 +/- 0.01 ml/hr/mg protein), the high-affinity site was considered more important in the DP metabolism at its therapeutic concentrations (i.e., 2-5 micrograms/ml or 5-14 microM).",A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),[ml] / [h·mg],0.03,186151,DB00280,Disopyramide
,8450476,Ki,EM inhibited the high-affinity site activity in a noncompetitive manner with the mean Ki of 19.5 +/- 1.3 microM (n = 4).,A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),μM,19.5,186152,DB00280,Disopyramide
,8450476,IC50,"An EM concentration associated with a 50% suppression of the DP metabolism at 30 microM (i.e., IC50) was 94 microM.(ABSTRACT TRUNCATED AT 250 WORDS)",A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450476/),μM,94,186153,DB00280,Disopyramide
,6882879,AUC free 0-9,AUC free 0-9 values were 30-60 per cent higher than expected in two subjects following 300 mg D due to an apparent dose-dependent decrease in D renal tubular secretion.,Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882879/),%,30-60,188237,DB00280,Disopyramide
,6882879,Renal clearance,Renal clearance of free D averaged 10.9 1 h-1.,Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882879/),[1] / [h],10.9,188238,DB00280,Disopyramide
,6882879,renal clearance,The renal clearance of MND averaged 10.3 1 h-1.,Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882879/),[1] / [h],10.3,188239,DB00280,Disopyramide
,1867965,Clearance,"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],7.9,188565,DB00280,Disopyramide
,1867965,Clearance,"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],4.6,188566,DB00280,Disopyramide
,1867965,volume of distribution (Vz),"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,89,188567,DB00280,Disopyramide
,1867965,volume of distribution (Vz),"Clearance and volume of distribution (Vz) of total drug were significantly (P less than 0.001) higher for the R-(-) enantiomer than the S-(+) enantiomer (7.9 vs 4.6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,50,188568,DB00280,Disopyramide
,1867965,clearance,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],34.6,188569,DB00280,Disopyramide
,1867965,clearance,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),[l] / [h],27.2,188570,DB00280,Disopyramide
,1867965,unbound volumes of distribution,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,258,188571,DB00280,Disopyramide
,1867965,unbound volumes of distribution,"The clearance of free drug was significantly (P less than 0.05) higher for the S-(+) enantiomer than that of the R-(-) enantiomer (34.6 +/- 5.4 l h-1 vs 27.2 +/- 5.6 l h-1), whereas no significant enantioselective difference in unbound volumes of distribution (258 +/- 38 l vs 226 +/- 42 l) could be demonstrated.",Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867965/),l,226,188572,DB00280,Disopyramide
,3653232,unbound clearance,The unbound clearance was 599 ml/min and the unbound renal clearance 310 ml/min.,Bioavailability of disopyramide in normal volunteers using unbound concentration. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653232/),[ml] / [min],599,192284,DB00280,Disopyramide
,3653232,unbound renal clearance,The unbound clearance was 599 ml/min and the unbound renal clearance 310 ml/min.,Bioavailability of disopyramide in normal volunteers using unbound concentration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653232/),[ml] / [min],310,192285,DB00280,Disopyramide
,3653232,terminal elimination rate constant of unbound drug,The terminal elimination rate constant of unbound drug was 0.180 h-1 after the i.v. dose and 0.203 h-1 after the oral dose.,Bioavailability of disopyramide in normal volunteers using unbound concentration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653232/),1/[h],0.180,192286,DB00280,Disopyramide
,3653232,terminal elimination rate constant of unbound drug,The terminal elimination rate constant of unbound drug was 0.180 h-1 after the i.v. dose and 0.203 h-1 after the oral dose.,Bioavailability of disopyramide in normal volunteers using unbound concentration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653232/),1/[h],0.203,192287,DB00280,Disopyramide
,3653232,absorption rate constant,The absorption rate constant was 0.53(-1) and the maximum peak concentration occurred after 3.2 h.,Bioavailability of disopyramide in normal volunteers using unbound concentration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653232/),-1,0.53,192288,DB00280,Disopyramide
,3653232,bioavailability,The bioavailability was 0.809 using the area under the unbound plasma concentration time curve.,Bioavailability of disopyramide in normal volunteers using unbound concentration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653232/),,0.809,192289,DB00280,Disopyramide
,3653232,bioavailability,"Although a saturable plasma protein binding was found in all subjects the bioavailability using the total concentration, in contrast to theoretical expectations, showed the same value (0.813) as the unbound concentrations.",Bioavailability of disopyramide in normal volunteers using unbound concentration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653232/),,0.813,192290,DB00280,Disopyramide
,1585394,bioavailabilities,"The bioavailabilities calculated from total and unbound plasma concentration-time curves were 99 +/- 23 and 89 +/- 27% of the dose, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),%,99,195307,DB00280,Disopyramide
,1585394,bioavailabilities,"The bioavailabilities calculated from total and unbound plasma concentration-time curves were 99 +/- 23 and 89 +/- 27% of the dose, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),%,89,195308,DB00280,Disopyramide
,1585394,elimination half-lives (t1/2),"The mean elimination half-lives (t1/2), volumes of distribution, and total body clearances (CL) of total and unbound DP were 3.15 +/- 0.64 and 2.50 +/- 0.37 h, 1.02 +/- 0.25 and 2.60 +/- 0.38 L/kg, and 3.79 +/- 0.82 and 13.12 +/- 2.60 ml/min/kg, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),h,3.15,195309,DB00280,Disopyramide
,1585394,volumes of distribution,"The mean elimination half-lives (t1/2), volumes of distribution, and total body clearances (CL) of total and unbound DP were 3.15 +/- 0.64 and 2.50 +/- 0.37 h, 1.02 +/- 0.25 and 2.60 +/- 0.38 L/kg, and 3.79 +/- 0.82 and 13.12 +/- 2.60 ml/min/kg, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),h,2.50,195310,DB00280,Disopyramide
,1585394,volumes of distribution,"The mean elimination half-lives (t1/2), volumes of distribution, and total body clearances (CL) of total and unbound DP were 3.15 +/- 0.64 and 2.50 +/- 0.37 h, 1.02 +/- 0.25 and 2.60 +/- 0.38 L/kg, and 3.79 +/- 0.82 and 13.12 +/- 2.60 ml/min/kg, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),[l] / [kg],1.02,195311,DB00280,Disopyramide
,1585394,total body clearances (CL),"The mean elimination half-lives (t1/2), volumes of distribution, and total body clearances (CL) of total and unbound DP were 3.15 +/- 0.64 and 2.50 +/- 0.37 h, 1.02 +/- 0.25 and 2.60 +/- 0.38 L/kg, and 3.79 +/- 0.82 and 13.12 +/- 2.60 ml/min/kg, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),[l] / [kg],2.60,195312,DB00280,Disopyramide
,1585394,total body clearances (CL),"The mean elimination half-lives (t1/2), volumes of distribution, and total body clearances (CL) of total and unbound DP were 3.15 +/- 0.64 and 2.50 +/- 0.37 h, 1.02 +/- 0.25 and 2.60 +/- 0.38 L/kg, and 3.79 +/- 0.82 and 13.12 +/- 2.60 ml/min/kg, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),[ml] / [kg·min],3.79,195313,DB00280,Disopyramide
,1585394,total body clearances (CL),"The mean elimination half-lives (t1/2), volumes of distribution, and total body clearances (CL) of total and unbound DP were 3.15 +/- 0.64 and 2.50 +/- 0.37 h, 1.02 +/- 0.25 and 2.60 +/- 0.38 L/kg, and 3.79 +/- 0.82 and 13.12 +/- 2.60 ml/min/kg, respectively.",Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585394/),[ml] / [kg·min],13.12,195314,DB00280,Disopyramide
,1820885,unbound clearance,"The mean unbound clearance of R(-) DP and S(+) DP were 8.59 and 14.9 ml/min/kg, respectively (p = 0.003).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),[ml] / [kg·min],8.59,202554,DB00280,Disopyramide
,1820885,unbound clearance,"The mean unbound clearance of R(-) DP and S(+) DP were 8.59 and 14.9 ml/min/kg, respectively (p = 0.003).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),[ml] / [kg·min],14.9,202555,DB00280,Disopyramide
,1820885,unbound renal clearance,"The mean unbound renal clearance of R(-) DP and S(+) DP were 6.26 and 8.75 ml/min/kg, respectively (p = 0.025).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),[ml] / [kg·min],6.26,202556,DB00280,Disopyramide
,1820885,unbound renal clearance,"The mean unbound renal clearance of R(-) DP and S(+) DP were 6.26 and 8.75 ml/min/kg, respectively (p = 0.025).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),[ml] / [kg·min],8.75,202557,DB00280,Disopyramide
,1820885,non renal clearance,"The non renal clearance of R(-) DP and S(+) DP averaged 2.32 and 6.19 ml/min/kg, respectively (p = 0.002).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),[ml] / [kg·min],2.32,202558,DB00280,Disopyramide
,1820885,non renal clearance,"The non renal clearance of R(-) DP and S(+) DP averaged 2.32 and 6.19 ml/min/kg, respectively (p = 0.002).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),[ml] / [kg·min],6.19,202559,DB00280,Disopyramide
,1820885,unbound volume of distribution,"The mean unbound volume of distribution of R(-) and S(+) DP were 225 and 381 liters, respectively (p = 0.023).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),l,225,202560,DB00280,Disopyramide
,1820885,unbound volume of distribution,"The mean unbound volume of distribution of R(-) and S(+) DP were 225 and 381 liters, respectively (p = 0.023).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),l,381,202561,DB00280,Disopyramide
,1820885,half-life,"The half-life of R(-) DP and S(+) DP averaged 4.17 and 3.91 hr, respectively (p = 0.21).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),h,4.17,202562,DB00280,Disopyramide
,1820885,half-life,"The half-life of R(-) DP and S(+) DP averaged 4.17 and 3.91 hr, respectively (p = 0.21).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),h,3.91,202563,DB00280,Disopyramide
,1820885,unbound fraction at steady-state,"The unbound fraction at steady-state of R(-) DP and S(+) DP averaged 12.5 and 7.5%, respectively (p = 0.002).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),%,12.5,202564,DB00280,Disopyramide
,1820885,unbound fraction at steady-state,"The unbound fraction at steady-state of R(-) DP and S(+) DP averaged 12.5 and 7.5%, respectively (p = 0.002).",Human pharmacokinetics and metabolism of disopyramide enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820885/),%,7.5,202565,DB00280,Disopyramide
,2471004,peak serum concentrations,"Mean peak serum concentrations of racemic disopyramide and its enantiomers were similar (2.7 to 3.1 mg/L), but clearance was stereo-specific [half-life (t1/2) of 1.99 h for S(+) vs. 2.79 h for R(-) disopyramide].",Hemodynamic and electrophysiologic effects of disopyramide enantiomers in a canine blood superfusion model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471004/),[mg] / [l],2.7 to 3.1,204017,DB00280,Disopyramide
,2471004,half-life (t1/2),"Mean peak serum concentrations of racemic disopyramide and its enantiomers were similar (2.7 to 3.1 mg/L), but clearance was stereo-specific [half-life (t1/2) of 1.99 h for S(+) vs. 2.79 h for R(-) disopyramide].",Hemodynamic and electrophysiologic effects of disopyramide enantiomers in a canine blood superfusion model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471004/),h,1.99,204018,DB00280,Disopyramide
,2471004,half-life (t1/2),"Mean peak serum concentrations of racemic disopyramide and its enantiomers were similar (2.7 to 3.1 mg/L), but clearance was stereo-specific [half-life (t1/2) of 1.99 h for S(+) vs. 2.79 h for R(-) disopyramide].",Hemodynamic and electrophysiologic effects of disopyramide enantiomers in a canine blood superfusion model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471004/),h,2.79,204019,DB00280,Disopyramide
,26556,absolute oral bioavailability,DP was absorbed rapidly and its absolute oral bioavailability was about 70%.,Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556/),%,70,205506,DB00280,Disopyramide
,26556,Plasma half-lives,"Plasma half-lives of DP were about 2.9 and 1.2 hr after the po and iv doses, respectively.",Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556/),h,2.9,205507,DB00280,Disopyramide
,26556,Plasma half-lives,"Plasma half-lives of DP were about 2.9 and 1.2 hr after the po and iv doses, respectively.",Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556/),h,1.2,205508,DB00280,Disopyramide
,3211990,plasma half life,"Peak plasma concentration and area under the curve (AUCo-oo) were 54% and 51% respectively higher in the elderly group, whereas plasma half life was virtually the same in both groups (about 9 hrs).",Disopyramide pharmacokinetics in the elderly after single oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3211990/),h,9,216990,DB00280,Disopyramide
,2427003,elimination half-life,"The elimination half-life varies from 4.5 to nine hours, and it can be even longer in cases of renal failure or myocardial infarction.","Disopyramide: clinical indications, pharmacokinetics and laboratory assessment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427003/),h,4.5 to nine,226175,DB00280,Disopyramide
,2427003,protein binding,"There exists an extremely variable degree of protein binding (10 to 70 percent), which is highly dependent on concentration.","Disopyramide: clinical indications, pharmacokinetics and laboratory assessment. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427003/),%,10 to 70,226176,DB00280,Disopyramide
,2189614,bioavailability,Pharmacokinetic studies have shown that oral absorption is rapid with bioavailability of 80-90%.,Mexiletine: pharmacology and therapeutic use. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),%,80-90,228858,DB00280,Disopyramide
,2189614,elimination half-life,Mexiletine is predominantly metabolized by the liver with elimination half-life of 9 to 12 hours.,Mexiletine: pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),h,9 to 12,228859,DB00280,Disopyramide
,6600029,volume of distribution,"Our data showed statistically significant circadian rhythms in the following pharmacokinetic parameters: highest volume of distribution = 3.91 +/- 0.21 l kg-1 at 2200 (circadian amplitude, half the peak-to-trough difference relative to the 24-hr mean multiplied by 100, is 34%); highest area under concentration curves = 16.06 +/- 1.03 micrograms ml-1 hr-1 at 0400 (circadian amplitude = 43%) and highest clearance = 3.04 +/- 0.19 l hr-1 kg-1 at 2200 (circadian amplitude = 21%).",Circadian phase dependent pharmacokinetics of disopyramide in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600029/),[l] / [kg],3.91,231306,DB00280,Disopyramide
,6600029,area under concentration curves,"Our data showed statistically significant circadian rhythms in the following pharmacokinetic parameters: highest volume of distribution = 3.91 +/- 0.21 l kg-1 at 2200 (circadian amplitude, half the peak-to-trough difference relative to the 24-hr mean multiplied by 100, is 34%); highest area under concentration curves = 16.06 +/- 1.03 micrograms ml-1 hr-1 at 0400 (circadian amplitude = 43%) and highest clearance = 3.04 +/- 0.19 l hr-1 kg-1 at 2200 (circadian amplitude = 21%).",Circadian phase dependent pharmacokinetics of disopyramide in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600029/),[μg] / [h·ml],16.06,231307,DB00280,Disopyramide
,6600029,clearance,"Our data showed statistically significant circadian rhythms in the following pharmacokinetic parameters: highest volume of distribution = 3.91 +/- 0.21 l kg-1 at 2200 (circadian amplitude, half the peak-to-trough difference relative to the 24-hr mean multiplied by 100, is 34%); highest area under concentration curves = 16.06 +/- 1.03 micrograms ml-1 hr-1 at 0400 (circadian amplitude = 43%) and highest clearance = 3.04 +/- 0.19 l hr-1 kg-1 at 2200 (circadian amplitude = 21%).",Circadian phase dependent pharmacokinetics of disopyramide in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600029/),[l] / [h·kg],3.04,231308,DB00280,Disopyramide
,3716823,"t1/2, beta","By measuring the free and total concentrations in plasma of parent compound and desisopropyldisopyramide (the main metabolite in humans) and the amounts excreted in urine it was found that disopyramide had a concentration dependent protein binding and that free and total concentrations could be described by a two-compartment model with a t1/2, beta of approximately 2 hours.",The pharmacokinetics and protein binding of disopyramide in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3716823/),h,2,235203,DB00280,Disopyramide
,3716823,total clearance,The total clearance of disopyramide in the pig was found to approximately 3 ml/min./kg which is about 3 times greater than in man.,The pharmacokinetics and protein binding of disopyramide in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3716823/),[ml] / [·kg·min],3,235204,DB00280,Disopyramide
,1762088,systemic clearance,"The pediatric age patients had the mean (+/- S.D.) systemic clearance of 15.0 +/- 3.8 and 12.7 +/- 3.9 ml/min/kg for unbound S- and R-DP, respectively, which were not only stereoselectively different (P less than .05) but also at least about twice greater than the reported normal adult values.",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),[ml] / [kg·min],15.0,238126,DB00280,Disopyramide
,1762088,systemic clearance,"The pediatric age patients had the mean (+/- S.D.) systemic clearance of 15.0 +/- 3.8 and 12.7 +/- 3.9 ml/min/kg for unbound S- and R-DP, respectively, which were not only stereoselectively different (P less than .05) but also at least about twice greater than the reported normal adult values.",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),[ml] / [kg·min],12.7,238127,DB00280,Disopyramide
,1762088,elimination half-life,"The mean postinfusion elimination half-life values for unbound S- and R-DP (2.7 +/- 0.5 and 2.8 +/- 0.4 hr, respectively) in pediatric patients were shorter than those reported from normal adults (approximately equal to 4 to 5 hr).",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),h,2.7,238128,DB00280,Disopyramide
,1762088,elimination half-life,"The mean postinfusion elimination half-life values for unbound S- and R-DP (2.7 +/- 0.5 and 2.8 +/- 0.4 hr, respectively) in pediatric patients were shorter than those reported from normal adults (approximately equal to 4 to 5 hr).",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),h,2.8,238129,DB00280,Disopyramide
,1762088,elimination half-life,"The mean postinfusion elimination half-life values for unbound S- and R-DP (2.7 +/- 0.5 and 2.8 +/- 0.4 hr, respectively) in pediatric patients were shorter than those reported from normal adults (approximately equal to 4 to 5 hr).",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),h,4 to 5,238130,DB00280,Disopyramide
,1762088,nonrenal,"The mean nonrenal (i.e., hepatic) clearance for unbound S- and R-DP (11.1 +/- 4.1 and 8.1 +/- 3.9 ml/min/kg, respectively) were also stereoselectively different (P less than .01) and accounted for approximately equal to 70% of the unbound systemic clearance of the respective enantiomers.",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),[ml] / [kg·min],11.1,238131,DB00280,Disopyramide
,1762088,nonrenal,"The mean nonrenal (i.e., hepatic) clearance for unbound S- and R-DP (11.1 +/- 4.1 and 8.1 +/- 3.9 ml/min/kg, respectively) were also stereoselectively different (P less than .01) and accounted for approximately equal to 70% of the unbound systemic clearance of the respective enantiomers.",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),[ml] / [kg·min],8.1,238132,DB00280,Disopyramide
,1762088,hepatic,"The mean nonrenal (i.e., hepatic) clearance for unbound S- and R-DP (11.1 +/- 4.1 and 8.1 +/- 3.9 ml/min/kg, respectively) were also stereoselectively different (P less than .01) and accounted for approximately equal to 70% of the unbound systemic clearance of the respective enantiomers.",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),[ml] / [kg·min],11.1,238133,DB00280,Disopyramide
,1762088,hepatic,"The mean nonrenal (i.e., hepatic) clearance for unbound S- and R-DP (11.1 +/- 4.1 and 8.1 +/- 3.9 ml/min/kg, respectively) were also stereoselectively different (P less than .01) and accounted for approximately equal to 70% of the unbound systemic clearance of the respective enantiomers.",Stereoselective disposition and metabolism of disopyramide in pediatric patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762088/),[ml] / [kg·min],8.1,238134,DB00280,Disopyramide
,15985054,Vd,"The final pharmacokinetic model was Cl (L/h)=3.75.TBW0.567.AGE-0.374.Conc(-0.719).1.48(DOSE>or=5), Vd (L/kg)=4.13 and k(a) (h-1)=0.363, where Cl is total body clearance, Vd is apparent volume of distribution, k(a) is absorption rate constant, TBW is total bodyweight (kg), AGE is age (years), Conc is the concentration of disopyramide (microg/mL), and DOSE>or=5=1 for patient received 5 mg/kg/day of disopyramide dosage or over and 0 otherwise.",Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985054/),[l] / [kg],4.13,244486,DB00280,Disopyramide
,15985054,k(a),"The final pharmacokinetic model was Cl (L/h)=3.75.TBW0.567.AGE-0.374.Conc(-0.719).1.48(DOSE>or=5), Vd (L/kg)=4.13 and k(a) (h-1)=0.363, where Cl is total body clearance, Vd is apparent volume of distribution, k(a) is absorption rate constant, TBW is total bodyweight (kg), AGE is age (years), Conc is the concentration of disopyramide (microg/mL), and DOSE>or=5=1 for patient received 5 mg/kg/day of disopyramide dosage or over and 0 otherwise.",Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15985054/),1/[h],0.363,244487,DB00280,Disopyramide
,8138963,affinity constant (Km),"The mean (+/- S.D.) affinity constant (Km) of the high-affinity component for S-(+)-DP (4.86 +/- 2.66 microM) was significantly (P < .05) lower than that for R-(-)-DP (24.61 +/- 17.52 microM), whereas no difference was observed between the maximum velocities (Vmax) for S-(+)- and R-(-)-DP.",Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138963/),μM,4.86,248812,DB00280,Disopyramide
,8138963,affinity constant (Km),"The mean (+/- S.D.) affinity constant (Km) of the high-affinity component for S-(+)-DP (4.86 +/- 2.66 microM) was significantly (P < .05) lower than that for R-(-)-DP (24.61 +/- 17.52 microM), whereas no difference was observed between the maximum velocities (Vmax) for S-(+)- and R-(-)-DP.",Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138963/),μM,24.61,248813,DB00280,Disopyramide
,7095921,plasma elimination half-life,"After an oral dose in healthy volunteers the plasma elimination half-life of total disopyramide was 8.65 +/- 1.37 h, and that of the non protein-bound disopyramide, 4.74 +/- 1.20 h.",The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),h,8.65,249448,DB00280,Disopyramide
,7095921,plasma elimination half-life,"After an oral dose in healthy volunteers the plasma elimination half-life of total disopyramide was 8.65 +/- 1.37 h, and that of the non protein-bound disopyramide, 4.74 +/- 1.20 h.",The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),h,4.74,249449,DB00280,Disopyramide
,7095921,protein binding,"The protein binding of disopyramide varied from 0.58 to nearly 1.0, and was concentration dependent.",The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),,0.58,249450,DB00280,Disopyramide
,7095921,protein binding,"The protein binding of disopyramide varied from 0.58 to nearly 1.0, and was concentration dependent.",The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),,1,249451,DB00280,Disopyramide
,7095921,elimination half-life,Its elimination half-life was 12.9 +/- 6.43 h.,The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),h,12.9,249452,DB00280,Disopyramide
,7095921,elimination half-lives,"The elimination half-lives of total disopyramide varied from 4.4 to 17.1 in post-surgery patients, and those of the renal patients were 10.6 and 8.7 h.",The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),h,4.4 to 17.1,249453,DB00280,Disopyramide
,7095921,elimination half-lives,"The elimination half-lives of total disopyramide varied from 4.4 to 17.1 in post-surgery patients, and those of the renal patients were 10.6 and 8.7 h.",The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),h,10.6,249454,DB00280,Disopyramide
,7095921,elimination half-lives,"The elimination half-lives of total disopyramide varied from 4.4 to 17.1 in post-surgery patients, and those of the renal patients were 10.6 and 8.7 h.",The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095921/),h,8.7,249455,DB00280,Disopyramide
,7437241,plasma elimination half-life,"3 Mean plasma elimination half-life in these patients was 12.7 h, which is substantially greater than that reported for normal subjects.",Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437241/),h,12.7,255314,DB00280,Disopyramide
,728284,biological half-life,"3 After intravenous administration, the following average pharmacokinetic parameters were found: biological half-life, 7.8 h; total clearance, 95 ml/min; renal clearance, 54 ml/min; apparent volume of distribution, 60 litres.",Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728284/),h,7.8,255969,DB00280,Disopyramide
,728284,total clearance,"3 After intravenous administration, the following average pharmacokinetic parameters were found: biological half-life, 7.8 h; total clearance, 95 ml/min; renal clearance, 54 ml/min; apparent volume of distribution, 60 litres.",Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728284/),[ml] / [min],95,255970,DB00280,Disopyramide
,728284,renal clearance,"3 After intravenous administration, the following average pharmacokinetic parameters were found: biological half-life, 7.8 h; total clearance, 95 ml/min; renal clearance, 54 ml/min; apparent volume of distribution, 60 litres.",Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728284/),[ml] / [min],54,255971,DB00280,Disopyramide
,728284,apparent volume of distribution,"3 After intravenous administration, the following average pharmacokinetic parameters were found: biological half-life, 7.8 h; total clearance, 95 ml/min; renal clearance, 54 ml/min; apparent volume of distribution, 60 litres.",Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728284/),l,60,255972,DB00280,Disopyramide
,3732373,drug clearance,"This was interpreted as being due to relatively high drug clearance, calculated as 6.7 +/- 1.5 l/h, compared to expected values of 3-4 l/h.",Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732373/),[l] / [h],6.7,264521,DB00280,Disopyramide
,3732373,drug clearance,"This was interpreted as being due to relatively high drug clearance, calculated as 6.7 +/- 1.5 l/h, compared to expected values of 3-4 l/h.",Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732373/),[l] / [h],3-4,264522,DB00280,Disopyramide
,3732373,Clearance,Clearance at this time was calculated to be 3.1 +/- 0.6 l/h.,Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732373/),[l] / [h],3.1,264523,DB00280,Disopyramide
,3392228,time to maximum concentration,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),h,5.5,271982,DB00280,Disopyramide
,3392228,maximum concentration,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],2.8,271983,DB00280,Disopyramide
,3392228,maximum concentration,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],2.0,271984,DB00280,Disopyramide
,3392228,maximum concentration,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],1.2,271985,DB00280,Disopyramide
,3392228,concentrations,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],2.8,271986,DB00280,Disopyramide
,3392228,concentrations,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],2.0,271987,DB00280,Disopyramide
,3392228,concentrations,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],1.2,271988,DB00280,Disopyramide
,3392228,24 hours,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],2.0,271989,DB00280,Disopyramide
,3392228,24 hours,"The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively.",Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),[μg] / [ml],1.2,271990,DB00280,Disopyramide
,3392228,Cmax to trough concentration ratio,A low Cmax to trough concentration ratio of 1.35 +/- 0.26 was observed after the initial dose.,Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392228/),,1.35,271991,DB00280,Disopyramide
,1756095,fractions,"The average fractions of (-)-(R)-DP and (+)-(S)-DP metabolized in vitro (4.7 +/- 2.7 and 7.1 +/- 4.2%, respectively, n = 4) were about 5-fold lower than the fractions metabolized in vivo (26.0 +/- 6.0 and 40.2 +/- 8.8%, respectively, n = 6).",In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756095/),,4.7,272250,DB00280,Disopyramide
,1756095,fractions,"The average fractions of (-)-(R)-DP and (+)-(S)-DP metabolized in vitro (4.7 +/- 2.7 and 7.1 +/- 4.2%, respectively, n = 4) were about 5-fold lower than the fractions metabolized in vivo (26.0 +/- 6.0 and 40.2 +/- 8.8%, respectively, n = 6).",In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756095/),,7.1,272251,DB00280,Disopyramide
,1756095,fractions,"The average fractions of (-)-(R)-DP and (+)-(S)-DP metabolized in vitro (4.7 +/- 2.7 and 7.1 +/- 4.2%, respectively, n = 4) were about 5-fold lower than the fractions metabolized in vivo (26.0 +/- 6.0 and 40.2 +/- 8.8%, respectively, n = 6).",In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756095/),,26,272252,DB00280,Disopyramide
,1756095,fractions,"The average fractions of (-)-(R)-DP and (+)-(S)-DP metabolized in vitro (4.7 +/- 2.7 and 7.1 +/- 4.2%, respectively, n = 4) were about 5-fold lower than the fractions metabolized in vivo (26.0 +/- 6.0 and 40.2 +/- 8.8%, respectively, n = 6).",In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1756095/),,40,272253,DB00280,Disopyramide
